Equity Profile

INSM

Insmed Incorporated

Health CareBiotechnology$20.4B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Insmed Incorporated is a biotechnology company focused on developing innovative therapies for patients with serious and rare diseases. Operating in the Health Care sector, Insmed aims to address unmet medical needs, particularly in respiratory diseases, making its work crucial for patients and healthcare providers alike.

Key Metrics to Watch

Revenue Growth

Investors will be keen to see if Insmed can demonstrate growth in revenue, which is critical for its long-term viability.

N/A

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

INSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-22.08%

Avg Stock Reaction

-1.20%

Last Quarter Recap

In the last quarter, Insmed reported an EPS of -$0.76, which was better than the expected -$0.90, leading to a positive surprise. However, the stock fell by over 23% the following day, indicating investor concerns despite the beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as Insmed has struggled with consistent performance in recent quarters. Investors are looking for signs of improvement in revenue and progress in its drug pipeline.

Bull Case

If Insmed can show significant revenue growth and positive updates on its drug pipeline, it could restore investor confidence and lead to a strong stock performance.

Bear Case

On the other hand, if the company fails to meet expectations for revenue growth or provides negative updates on its pipeline, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Insmed's drug pipeline, particularly for its lead product?

Investors will closely watch for updates on clinical trials and potential approvals, as these will significantly impact future revenue.

Can Insmed demonstrate any revenue growth this quarter?

Given the company's recent struggles, showing revenue growth is crucial for restoring investor confidence and validating its business model.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Insmed's drug pipeline to deliver positive results, as recent clinical trial updates have shown promise that could translate into revenue sooner than expected.

Supporting Evidence

Insmed's recent EPS surprise indicates that the company may be performing better than anticipated.

The options market is pricing in a significant move, suggesting that investors expect volatility and potential positive news.

Key Risk

If the drug pipeline shows significant progress, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining the company's ability to recover from recent performance issues and regain investor trust.

Bull Confirmed If

Demonstrating revenue growth of at least 10% quarter-over-quarter would confirm the bull case.

Bear Confirmed If

Failing to show any revenue growth or negative updates on the drug pipeline would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.56%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±21.6% while INSM has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

92.2%

Calls (408K)P/C Ratio: 1.13Puts (123K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.5M

10,699 sh

1 insider

Net

$1.5M

Net selling

Most Active Insiders· 4 open-market trades

Chair and CEOLewis William
$1.5M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insmed beats expectations and raises guidance, history suggests a potential stock increase of around 16.33%, confirming a positive turnaround.

In-Line / Cautious

If results are in line but management expresses caution, the stock may experience a muted reaction, reflecting ongoing investor skepticism.

Miss

If Insmed misses expectations, history suggests a decline of approximately 1.98%, reinforcing concerns about its growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the clinical trial status of Insmed's lead product.
2Any commentary on expected revenue growth for the upcoming quarters.
3Insights into management's strategy for addressing recent performance challenges.
4Details on any new partnerships or collaborations that could enhance the pipeline.
5Feedback from analysts regarding the competitive landscape in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Revenue Growth

Investors will be keen to see if Insmed can demonstrate growth in revenue, which is critical for its long-term viability.

N/A

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

INSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-22.08%

Avg Stock Reaction

-1.20%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as Insmed has struggled with consistent performance in recent quarters. Investors are looking for signs of improvement in revenue and progress in its drug pipeline.

Bull Case

If Insmed can show significant revenue growth and positive updates on its drug pipeline, it could restore investor confidence and lead to a strong stock performance.

Bear Case

On the other hand, if the company fails to meet expectations for revenue growth or provides negative updates on its pipeline, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Insmed's drug pipeline, particularly for its lead product?

Investors will closely watch for updates on clinical trials and potential approvals, as these will significantly impact future revenue.

Can Insmed demonstrate any revenue growth this quarter?

Given the company's recent struggles, showing revenue growth is crucial for restoring investor confidence and validating its business model.

Edge

What the Street Is Missing

Why consensus could be wrong

Supporting Evidence

Insmed's recent EPS surprise indicates that the company may be performing better than anticipated.

The options market is pricing in a significant move, suggesting that investors expect volatility and potential positive news.

Key Risk

If the drug pipeline shows significant progress, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining the company's ability to recover from recent performance issues and regain investor trust.

Bull Confirmed If

Demonstrating revenue growth of at least 10% quarter-over-quarter would confirm the bull case.

Bear Confirmed If

Failing to show any revenue growth or negative updates on the drug pipeline would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.56%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±21.6% while INSM has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

92.2%

Calls (408K)P/C Ratio: 1.13Puts (123K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.5M

10,699 sh

1 insider

Net

$1.5M

Net selling

Most Active Insiders· 4 open-market trades

Chair and CEOLewis William
$1.5M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insmed beats expectations and raises guidance, history suggests a potential stock increase of around 16.33%, confirming a positive turnaround.

In-Line / Cautious

If results are in line but management expresses caution, the stock may experience a muted reaction, reflecting ongoing investor skepticism.

Miss

If Insmed misses expectations, history suggests a decline of approximately 1.98%, reinforcing concerns about its growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the clinical trial status of Insmed's lead product.
2Any commentary on expected revenue growth for the upcoming quarters.
3Insights into management's strategy for addressing recent performance challenges.
4Details on any new partnerships or collaborations that could enhance the pipeline.
5Feedback from analysts regarding the competitive landscape in the biotechnology sector.